Hosted By: Andrea Charles
Tags : aptuit | cro | clinical development | biomarker | Mauro Corsi | Phil Gerrard | Assay Development | Vitro Profiling | Preclinical Technologies | Sergio Raimondo | Preclinical Safety | Preclinical Pharmacology | Mark Hembarsky | Stefano Zancan | Clinical Trial Management | therapeutic candidates | investment | early clinical development | sponsor-CRO
About this Podcast...
In this podcast Mark Hembarsky, Vice President and Site Leader of the Aptuit Medicines Research Centre in Verona, Italy, and his colleagues Mauro Corsi, Head of Assay Development and In Vitro Profiling Preclinical Technologies, Sergio Raimondo, Head of Scientific Strategy Preclinical Safety, Phil Gerrard Head of Preclinical Pharmacology and Stefano Zancan, Head of Clinical Trial Management, join Andrea Charles from Pharma IQ, to share their scientific and technological expertise and provide an insight into the Aptuit Medicines Research Centre.
In this interview they discuss improving the success rates of therapeutic candidates in clinical development, making more efficient go/no-go decisions, challenges and investment considerations for biomarkers in early clinical development and the changing dynamics of the sponsor-CRO relationship.
Have Your Say
Rate this feature and give us your feedback in the comments section below
By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product.